APGE stock intrinsic value fair value estimate & owner earnings analysis

Apogee Therapeutics is a clinical-stage biotech with no products on the market and no revenue. Its lead antibody, zumilokibart (APG777), is a long-acting injection aimed at atopic dermatitis; the company is also developing combination programs with APG990 and APG333, and plans to extend to asthma and eosinophilic esophagitis. In Part A of its Phase 2 APEX trial (123 adults), zumilokibart reduced eczema severity (EASI) by 71.0% versus 33.8% on placebo at week 16. Part B (347 patients) finished enrolling in January 2026, with topline results expected in the second quarter of 2026; we have not reviewed those results, so they are not reflected here. The company said it plans to start a Phase 3 atopic dermatitis trial in the second half of 2026, which would allow a potential launch in 2029. The business loses money by design. Owner earnings (operating cash flow, less working-capital swings, less stock compensation, less capital spending) were about $(90)M in 2023, $(201)M in 2024 and $(278)M in 2025, or $(3.61), $(3.64) and $(4.58) per share. Operating cash outflow in the first half of 2026 was $127.0M. The company has paid no dividends. There is no borrowing on the balance sheet that we could identify; lease obligations are small and are already inside operating cash flow. Stock-based compensation is treated as a real cost. Because nothing here earns money today, the value rests on what the company holds. At June 30, 2026 it had $105.6M of cash and $866.4M of marketable securities, together $971.9M, equal to about $12.88 per share on 75.4M diluted shares (second-quarter weighted average; the count will differ from shares outstanding and will rise with any new equity). We excluded any long-term securities at that date because we did not confirm the amount. The 2025 annual report said existing cash and securities should fund operations into the second half of 2028. The cash is the only asset we can point to with certainty. We give no value to the drug pipeline in any case. Good Phase 2 data and a planned Phase 3 are real, but approval, launch and sales have not happened and none is contracted, so they are not secured growth. What a reader should know is that this leaves out the possibility, which is real, that the pipeline is worth much more than the cash; our cases measure what is left of the cash under different spending paths. The spending figures below are our assumptions, based on the first-half 2026 burn of about $254M annualized (2 x $127.0M). Bear: Phase 3 is funded and fails. We assume two years of spending at the current rate ($508M) and $50M of wind-down costs (assumption), leaving about $414M, or $5.49 per share. Business worth is the remaining cash; it owes no borrowings; the difference is $5.49 per share. Base: the company spends about one more year at the current rate ($254M) with no value created, then winds down at an assumed cost of $25M, leaving about $693M, or $9.18 per share. Bull: the company stops spending promptly and winds down at an assumed $25M, leaving about $947M, or $12.55 per share. Even the bull case credits no drug value, because none is yet secured. Each case has no debt to refinance. What we would be wrong about: the pipeline could prove valuable, which would make every case too low; or trials and equity raises could consume cash faster and dilute holders, which would make the cases too high. We also could not itemize about $18M of the gap between the 2025 net loss plus stock compensation and operating cash flow, and our working-capital figure excludes prepaid-asset changes, which the filings did not tag separately. Margin-of-safety price: our confidence in the earnings level is high only in the sense that it is a steady, growing loss; our confidence in what the company is worth is low because the pipeline is binary. The worst plausible outcome is a failed Phase 3 after two more years of spending and large dilution on the way, and the structure survives that because there is no debt and the assets are cash. If we are wrong about spending, or about how long the company waits to stop, shares could be worth well under $5. The business pays nothing in the meantime and spends roughly $3 a share of its cash each year, so the price assumes a holding period only as long as trial progress is visible. The margin-of-safety price is $6.00, a price near what a failed Phase 3 would leave per share; from that price, a successful trial result would imply a 20% annual return.